A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)

Atopic Dermatitis Clinical Trial

Official title:

A Phase 1/2A, Randomized, Placebo-Controlled, Single-Ascending Dose (Part A, Participant- and Investigator-Blind) and Repeat-Dose (Part B, Participant-, Investigator-, and Sponsor-Blind) Study to Investigate the Safety, Pharmacokinetics, and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05277571
• Other study ID #: UP0110
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: March 7, 2022
• Est. completion date: January 30, 2025

Study information

• Verified date: May 2024
• Source: UCB Pharma
• Contact: UCB Cares
• Phone: 1-844-599-2273 (USA)
• Email: ucbcares[@]ucb.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB1381 (intravenous and subcutaneous) in healthy study participants and after repeat intravenous dosing in study participants with atopic dermatitis. Efficacy will be assessed following repeat intravenous dosing versus placebo in study participants with atopic dermatitis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 152
• Est. completion date: January 30, 2025
• Est. primary completion date: January 30, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

Part A Healthy study participants

• Participant must be 18 to 55 years of age inclusive at the time of signing the informed consent form (ICF)

• Participant must be overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring

• Participant has a body mass index (BMI) within the range 18 to 30 kg/m2 (inclusive)

• Participant can be male or female and must agree to use contraception

Part B Participants with moderate to severe Atopic dermatitis (AtD)

• Participant must be 18 to 65 years of age inclusive at the time of signing the ICF

• Participant has moderate or severe AtD that has been present for at least 12 months prior to initiating the study (signing of the ICF) and with:

• A validated Investigator Global Assessment (vIGA) score =3 at Screening and Baseline

• An Eczema Area and Severity Index (EASI) score of =14 at Screening and =16 at Baseline

• Pruritis Numerical Rating Scale (NRS) =3 at Screening and Baseline

-=10 % body surface area (BSA) of AtD involvement at Screening and Baseline

• Either documented recent history (within 6 months before the Screening Visit) of inadequate response to treatment with topical medications (regular use of topical corticosteroids [TCS] or topical calcineurin inhibitors [TCIs]) or when topical treatments are confirmed to be otherwise medically inadvisable (eg, because of important side effects or safety risks)

• Participant has a BMI within the range 18 to 35 kg/m2 (inclusive)

Exclusion Criteria:

Part A Healthy study participants

• Participant has a history or presence of any medical or psychiatric condition, physical examination finding, laboratory test result, electrocardiogram (ECG), or vital sign that, in the opinion of the investigator, could significantly alter the absorption, metabolism, or elimination of drugs; constitute a risk when taking the study intervention; or interfere with the interpretation of data

• Participant has a known hypersensitivity to any components of the investigational medicinal product (IMP) or other biologic drugs (including humanized monoclonal antibodies (mAbs)), clinically significant drug allergies, or history of severe adverse reactions after drug administration

• Participant has a past history of inflammatory bowel disease (includes Crohn's disease and ulcerative colitis)

• Participant has previously been randomized in this study

• Participant has participated in another study of an IMP or has received any biologic agent (such as mAbs, including marketed drugs and including biologic agents that target interleukin (IL)-13 or IL-22) within the 30 days prior to Screening or 5 half-lives (whichever is longer), if this information can be validated by the investigator

Part B Participants with moderate to severe AtD

• Participant has a history or presence of any medical or psychiatric condition, physical examination finding, laboratory test result, electrocardiogram (ECG), or vital sign that, in the opinion of the investigator, could significantly alter the absorption, metabolism, or elimination of drugs; constitute a risk when taking the study intervention; or interfere with the interpretation of data

• Participant has a known hypersensitivity to any components of the IMP or other biologic drugs (including humanized mAbs), clinically significant drug allergies, or history of severe adverse reactions after drug administration

• Participant has a past history of inflammatory bowel disease (includes Crohn's disease and ulcerative colitis)

• Participant has had pharmaceutically active topical therapies for AtD (including mild topical corticosteroids (TCS)) within 2 weeks of the Baseline Visit (corticosteroids, cyclosporin or other calcineurin inhibitors [eg, tacrolimus, pimecrolimus])

• Participant has received phototherapy or systemic non-biologic therapies for AtD within 4 weeks of the Baseline Visit (including moderate/strong corticosteroids, cyclosporine A or other calcineurin inhibitors, mycophenolate mofetil, azathioprine, methotrexate, or any alternative medicine for AtD, eg, traditional Chinese medicine)

• Participant has previously used a biologic that affects IL-13 or IL-22 pathways, or any JAK inhibitor (including marketed and/or experimental treatments), within 30 days or 5 half-lives (whichever is longer) of the Baseline Visit. Previous use of biologics affecting IL-13 or IL-22 pathways is only accepted if treatment was stopped due to reasons other than inadequate efficacy and safety (eg, administrative reasons, poor convenience, poor access to drug)

• Participant has received any prescription or nonprescription medicines, including over the counter remedies and herbal and dietary supplements (other than vitamins within recommended daily dose limits) within 14 days (or 5 half-lives of the respective drug, whichever is longer) prior to the Baseline Visit, other than contraceptives (oral, implant, or intrauterine devices) or occasional use of analgesics such as paracetamol (acetaminophen, with or without caffeine, with a maximal dose of 4g/day and 10g/14 days) or intranasal corticosteroids for seasonal rhinitis or inhaled bronchodilators and low dose inhaled corticosteroids for mild asthma. In case of uncertainty, the UCB Development Physician should be consulted

• Participant has previously been randomized in this study

• Participant has participated in previous studies with a biologic that affects IL-13 or IL-22 pathways, or any JAK inhibitor (including marketed and/or experimental treatments), within 30 days or 5 half-lives (whichever is longer) of the Baseline Visit. Previous use of biologics affecting IL-13 or IL-22 pathways is only accepted if treatment was stopped due to reasons other than inadequate efficacy and safety (eg, administrative reasons, poor convenience, poor access to drug)

• Participant has participated in another study of an IMP within 30 days or 5 half-lives (whichever is longer) of the Baseline Visit or is currently participating in another study of an IMP

Related Conditions & MeSH terms

• Atopic Dermatitis
• Dermatitis
• Dermatitis, Atopic
• Eczema

Intervention

Biological:
• UCB1381
UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B

Drug:
• Placebo
Placebo will be administered iv or sc in Part A and iv in Part B to maintain the blinding.

Locations

Country	Name	City	State
United States	Up0110 125	Beverly Hills	California
United States	Up0110 108	Clearwater	Florida
United States	Up0110 111	College Park	Georgia
United States	Up0110 120	Dallas	Texas
United States	Up0110 103	DeLand	Florida
United States	Up0110 101	Glendale	California
United States	Up0110 126	Lake Forest	California
United States	Up0110 116	Los Angeles	California
United States	Up0110 109	Miami Lakes	Florida
United States	Up0110 114	Minneapolis	Minnesota
United States	Up0110 107	New York	New York
United States	Up0110 129	New York	New York
United States	Up0110 112	Normal	Illinois
United States	Up0110 117	North Little Rock	Arkansas
United States	Up0110 121	Northridge	California
United States	Up0110 106	Ocala	Florida
United States	Up0110 104	Oklahoma City	Oklahoma
United States	Up0110 119	Philadelphia	Pennsylvania
United States	Up0110 102	Saint Petersburg	Florida
United States	Up0110 123	Sherman Oaks	California
United States	Up0110 105	Tampa	Florida
United States	Up0110 127	Valencia	California
United States	Up0110 118	West Lafayette	Indiana
United States	Up0110 124	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
UCB Biopharma SRL

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidents of treatment-emergent adverse events (TEAEs) from Baseline through the End of Study (EOS) Visit (Week 12) in Part A	An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study medication.	From Baseline up to Week 12 in Part A
Primary	Incidents of treatment-emergent serious adverse events (TESAEs) from Baseline through the EOS Visit (Week 12) in Part A	A serious adverse event (SAE) is any untoward medical occurrence that at any dose: Results in death; Is life-threatening; Requires inpatient hospitalisation or prolongation of existing hospitalisation; Results in persistent or significant disability/incapacity, or; Is a congenital anomaly/birth defect; Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above	From Baseline up to Week 12 in Part A
Primary	Incidents of TEAEs from Baseline through the EOS Visit (Week 22) in Part B	An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study medication.	From Baseline up to Week 22 in Part B
Primary	Incidents of TESAEs from Baseline through the EOS Visit (Week 22) in Part B	A serious adverse event (SAE) is any untoward medical occurrence that at any dose: Results in death; Is life-threatening; Requires inpatient hospitalisation or prolongation of existing hospitalisation; Results in persistent or significant disability/incapacity, or; Is a congenital anomaly/birth defect; Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above	From Baseline up to Week 22 in Part B
Primary	=75% improvement vs Baseline (Yes/No) in Eczema Area and Severity Index score (EASI75) at Week 12 in Part B	The Eczema Area and Severity Index (EASI) is a validated scoring system that grades the physical signs of atopic dermatitis/eczema. A participant's EASI is scored through evaluation of 4 body regions: Head and neck; Trunk; Upper extremities; Lower extremities; The severity of disease is evaluated by assessing each of 4 clinical signs for each area: Erythema; Edema/papulation; Excoriation; Lichenification The severity of each clinical sign is scored as: 0=None, 1=Mild, 2=Moderate, 3=Severe.	From Baseline up to Week 12 in Part B
Secondary	UCB1381 Cmax from Baseline through the EOS Visit (Week 12) in Part A	Cmax: Maximum observed concentration	From Baseline up to Week 12 in Part A
Secondary	UCB1381 Tmax from Baseline through the EOS Visit (Week 12) in Part A	Tmax: Time of observed Cmax	From Baseline up to Week 12 in Part A
Secondary	UCB1381 AUC(0-t) from Baseline through the EOS Visit (Week 12) in Part A	AUC(0-t): Area under the concentration-time curve from time zero to the time of last detectable concentration.	From Baseline up to Week 12 in Part A
Secondary	UCB1381 AUC from Baseline through the EOS Visit (Week 12) in Part A	AUC: Area under the concentration-time curve from time zero to infinity.	From Baseline up to Week 12 in Part A
Secondary	UCB1381 F% from Baseline through the EOS Visit (Week 12) in Part A	F%: Bioavailability of subcutaneous administration	From Baseline up to Week 12 in Part A
Secondary	Percent change from Baseline in EASI score at Week 12 in Part B	The Eczema Area and Severity Index (EASI) is a validated scoring system that grades the physical signs of atopic dermatitis/eczema. A participant's EASI is scored through evaluation of 4 body regions: Head and neck; Trunk; Upper extremities; Lower extremities; The severity of disease is evaluated by assessing each of 4 clinical signs for each area: Erythema; Edema/papulation; Excoriation; Lichenification The severity of each clinical sign is scored as: 0=None, 1=Mild, 2=Moderate, 3=Severe.	From Baseline up to Week 12 in Part B
Secondary	=50% improvements vs Baseline (Yes/No) in EASI score (EASI50) at Week 12 in Part B	The Eczema Area and Severity Index (EASI) is a validated scoring system that grades the physical signs of atopic dermatitis/eczema. A participant's EASI is scored through evaluation of 4 body regions: Head and neck; Trunk; Upper extremities; Lower extremities; The severity of disease is evaluated by assessing each of 4 clinical signs for each area: Erythema; Edema/papulation; Excoriation; Lichenification The severity of each clinical sign is scored as: 0=None, 1=Mild, 2=Moderate, 3=Severe.	From Baseline up to Week 12 in Part B
Secondary	=90% improvements vs Baseline (Y/N) in EASI score (EASI90) at Week 12 in Part B	The Eczema Area and Severity Index (EASI) is a validated scoring system that grades the physical signs of atopic dermatitis/eczema. A participant's EASI is scored through evaluation of 4 body regions: Head and neck; Trunk; Upper extremities; Lower extremities; The severity of disease is evaluated by assessing each of 4 clinical signs for each area: Erythema; Edema/papulation; Excoriation; Lichenification The severity of each clinical sign is scored as: 0=None, 1=Mild, 2=Moderate, 3=Severe.	From Baseline up to Week 12 in Part B
Secondary	Validated Investigator Global Assessment (vIGA) score of 0 or 1 (Y/N) at Week 12 in Part B	vIGA: Validated Investigator Global Assessment score is using descriptors that best describe the overall appearance of the lesions at a given time point. Assessment: vIGA 0=clear, vIGA 1=almost clear, vIGA 2=mild, vIGA 3=moderate, vIGA 4=severe	From Baseline up to Week 12 in Part B
Secondary	UCB1381 Cmax at week 12 after the final dose in Part B	Cmax: Maximum observed concentration	From Baseline up to Week 12 in Part B
Secondary	UCB1381 Tmax at week 12 after the final dose in Part B	Tmax: Time of observed Cmax	From Baseline up to Week 12 in Part B
Secondary	UCB1381 AUCtau at week 12 after the final dose in Part B	AUCtau: Area under the curve for the dosing interval after the final dose.	From Baseline up to Week 12 in Part B